Sanjay Khedia, MD
Internal Medicine · Covina, CANPI 1326063801
Payments from drug & device makers
Across 351 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$638
- Boehringer Ingelheim$561
- Novo Nordisk$435
- Teva Pharmaceuticals USA, Inc.$404
- AbbVie$298
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,60397%
- Education$1733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 90 | $1,342 |
| AstraZeneca(2 entities) | 28 | $638 |
| Boehringer Ingelheim | 27 | $561 |
| Novo Nordisk | 25 | $435 |
| Teva Pharmaceuticals USA, Inc. | 17 | $404 |
| AbbVie(2 entities) | 17 | $298 |
| Lilly USA, LLC | 14 | $284 |
| Novartis | 11 | $235 |
| Astellas Pharma US Inc | 7 | $234 |
| Sanofi-aventis U.S. LLC | 12 | $202 |
| Pfizer | 11 | $198 |
| Gilead | 9 | $193 |
| Bayer | 7 | $187 |
| Sunovion Pharmaceuticals Inc. | 11 | $161 |
| E.r. Squibb & Sons, L.L.C. | 7 | $140 |
| Abbott | 6 | $112 |
| Madrigal Pharmaceuticals | 3 | $105 |
| Johnson & Johnson | 4 | $100 |
| GSK | 3 | $84 |
| Galderma Laboratories, L.p. | 4 | $83 |
| Exact Sciences | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $63 |
| Ardelyx, Inc. | 2 | $58 |
| Dexcom, Inc. | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Merck | 2 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Lundbeck LLC | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
How this compares
$6,777 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 277 | $138,115 |
| ProliaDenosumab | 81 | $134,394 |
| OzempicSemaglutide | 134 | $132,129 |
| JanuviaSitagliptin Phosphate | 269 | $108,212 |
| JardianceEmpagliflozin | 155 | $107,270 |
| FarxigaDapagliflozin Propanediol | 111 | $94,295 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $66,432 |
| GemtesaVibegron | 122 | $63,919 |
| XareltoRivaroxaban | 68 | $46,302 |
| LinzessLinaclotide | 57 | $40,256 |
| MounjaroTirzepatide | 37 | $38,125 |
| JanumetSitagliptin Phos/Metformin Hcl | 52 | $23,294 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $22,834 |
| MyrbetriqMirabegron | 52 | $22,668 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $20,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Combivent Respimat | $561 | $157,352227 claims |
| PfizerEliquis, Retacrit | $198 | $147,906303 claims |
| AmgenProlia | $1,342 | $134,39481 claims |
| Novo NordiskOzempic | $435 | $132,129134 claims |
| MerckJanuvia, Janumet | $34 | $131,506321 claims |
| AstraZenecaFarxiga, Brilinta | $638 | $102,688130 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $84 | $87,326145 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $64 | $63,919122 claims |
| Johnson & JohnsonXarelto, Procrit | $100 | $56,59198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $46,77359 claims |
| AbbVieLinzess | $298 | $40,25657 claims |
| Astellas Pharma US IncMyrbetriq | $234 | $22,66852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Covina
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.